Seroprevalence of antibodies against SARS-CoV-2 and risk of COVID-19 in Navarre, Spain, May to July 2022

In Navarre, Spain, in May 2022, the seroprevalence of anti-nucleocapsid (N) and anti-spike (S) antibodies of SARS-CoV-2 was 58.9% and 92.7%, respectively. The incidence of confirmed COVID-19 thereafter through July was lower in people with anti-N antibodies (adjusted odds ratio (aOR) = 0.08; 95% con...

Descripción completa

Detalles Bibliográficos
Autores principales: Castilla, Jesús, Lecea, Óscar, Martín Salas, Carmen, Quílez, Delia, Miqueleiz, Ana, Trobajo-Sanmartín, Camino, Navascués, Ana, Martínez-Baz, Iván, Casado, Itziar, Burgui, Cristina, Egüés, Nerea, Ezpeleta, Guillermo, Ezpeleta, Carmen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2022
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389855/
https://www.ncbi.nlm.nih.gov/pubmed/35983774
http://dx.doi.org/10.2807/1560-7917.ES.2022.27.33.2200619
_version_ 1784770546413600768
author Castilla, Jesús
Lecea, Óscar
Martín Salas, Carmen
Quílez, Delia
Miqueleiz, Ana
Trobajo-Sanmartín, Camino
Navascués, Ana
Martínez-Baz, Iván
Casado, Itziar
Burgui, Cristina
Egüés, Nerea
Ezpeleta, Guillermo
Ezpeleta, Carmen
author_facet Castilla, Jesús
Lecea, Óscar
Martín Salas, Carmen
Quílez, Delia
Miqueleiz, Ana
Trobajo-Sanmartín, Camino
Navascués, Ana
Martínez-Baz, Iván
Casado, Itziar
Burgui, Cristina
Egüés, Nerea
Ezpeleta, Guillermo
Ezpeleta, Carmen
author_sort Castilla, Jesús
collection PubMed
description In Navarre, Spain, in May 2022, the seroprevalence of anti-nucleocapsid (N) and anti-spike (S) antibodies of SARS-CoV-2 was 58.9% and 92.7%, respectively. The incidence of confirmed COVID-19 thereafter through July was lower in people with anti-N antibodies (adjusted odds ratio (aOR) = 0.08; 95% confidence interval (CI): 0.05–0.13) but not with anti-S antibodies (aOR = 1.06; 95% CI: 0.47–2.38). Hybrid immunity, including anti-N antibodies induced by natural exposure to SARS-CoV-2, seems essential in preventing Omicron COVID-19 cases.
format Online
Article
Text
id pubmed-9389855
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher European Centre for Disease Prevention and Control (ECDC)
record_format MEDLINE/PubMed
spelling pubmed-93898552022-09-13 Seroprevalence of antibodies against SARS-CoV-2 and risk of COVID-19 in Navarre, Spain, May to July 2022 Castilla, Jesús Lecea, Óscar Martín Salas, Carmen Quílez, Delia Miqueleiz, Ana Trobajo-Sanmartín, Camino Navascués, Ana Martínez-Baz, Iván Casado, Itziar Burgui, Cristina Egüés, Nerea Ezpeleta, Guillermo Ezpeleta, Carmen Euro Surveill Rapid Communication In Navarre, Spain, in May 2022, the seroprevalence of anti-nucleocapsid (N) and anti-spike (S) antibodies of SARS-CoV-2 was 58.9% and 92.7%, respectively. The incidence of confirmed COVID-19 thereafter through July was lower in people with anti-N antibodies (adjusted odds ratio (aOR) = 0.08; 95% confidence interval (CI): 0.05–0.13) but not with anti-S antibodies (aOR = 1.06; 95% CI: 0.47–2.38). Hybrid immunity, including anti-N antibodies induced by natural exposure to SARS-CoV-2, seems essential in preventing Omicron COVID-19 cases. European Centre for Disease Prevention and Control (ECDC) 2022-08-18 /pmc/articles/PMC9389855/ /pubmed/35983774 http://dx.doi.org/10.2807/1560-7917.ES.2022.27.33.2200619 Text en This article is copyright of the authors or their affiliated institutions, 2022. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.
spellingShingle Rapid Communication
Castilla, Jesús
Lecea, Óscar
Martín Salas, Carmen
Quílez, Delia
Miqueleiz, Ana
Trobajo-Sanmartín, Camino
Navascués, Ana
Martínez-Baz, Iván
Casado, Itziar
Burgui, Cristina
Egüés, Nerea
Ezpeleta, Guillermo
Ezpeleta, Carmen
Seroprevalence of antibodies against SARS-CoV-2 and risk of COVID-19 in Navarre, Spain, May to July 2022
title Seroprevalence of antibodies against SARS-CoV-2 and risk of COVID-19 in Navarre, Spain, May to July 2022
title_full Seroprevalence of antibodies against SARS-CoV-2 and risk of COVID-19 in Navarre, Spain, May to July 2022
title_fullStr Seroprevalence of antibodies against SARS-CoV-2 and risk of COVID-19 in Navarre, Spain, May to July 2022
title_full_unstemmed Seroprevalence of antibodies against SARS-CoV-2 and risk of COVID-19 in Navarre, Spain, May to July 2022
title_short Seroprevalence of antibodies against SARS-CoV-2 and risk of COVID-19 in Navarre, Spain, May to July 2022
title_sort seroprevalence of antibodies against sars-cov-2 and risk of covid-19 in navarre, spain, may to july 2022
topic Rapid Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389855/
https://www.ncbi.nlm.nih.gov/pubmed/35983774
http://dx.doi.org/10.2807/1560-7917.ES.2022.27.33.2200619
work_keys_str_mv AT castillajesus seroprevalenceofantibodiesagainstsarscov2andriskofcovid19innavarrespainmaytojuly2022
AT leceaoscar seroprevalenceofantibodiesagainstsarscov2andriskofcovid19innavarrespainmaytojuly2022
AT martinsalascarmen seroprevalenceofantibodiesagainstsarscov2andriskofcovid19innavarrespainmaytojuly2022
AT quilezdelia seroprevalenceofantibodiesagainstsarscov2andriskofcovid19innavarrespainmaytojuly2022
AT miqueleizana seroprevalenceofantibodiesagainstsarscov2andriskofcovid19innavarrespainmaytojuly2022
AT trobajosanmartincamino seroprevalenceofantibodiesagainstsarscov2andriskofcovid19innavarrespainmaytojuly2022
AT navascuesana seroprevalenceofantibodiesagainstsarscov2andriskofcovid19innavarrespainmaytojuly2022
AT martinezbazivan seroprevalenceofantibodiesagainstsarscov2andriskofcovid19innavarrespainmaytojuly2022
AT casadoitziar seroprevalenceofantibodiesagainstsarscov2andriskofcovid19innavarrespainmaytojuly2022
AT burguicristina seroprevalenceofantibodiesagainstsarscov2andriskofcovid19innavarrespainmaytojuly2022
AT eguesnerea seroprevalenceofantibodiesagainstsarscov2andriskofcovid19innavarrespainmaytojuly2022
AT ezpeletaguillermo seroprevalenceofantibodiesagainstsarscov2andriskofcovid19innavarrespainmaytojuly2022
AT ezpeletacarmen seroprevalenceofantibodiesagainstsarscov2andriskofcovid19innavarrespainmaytojuly2022

Ejemplares similares